Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton's tyrosine kinase or BTK, in patients with relapsed/refractory Waldenström's macroglobulinemia or WM at the 12th International Workshop on Waldenstrom's Macroglobulinemia or IWWM-12.
NX-5948 demonstrated robust clinical activity, with objective responses observed in seven of nine evaluable Waldenstrom's patients (77.8%) in the ongoing Phase 1a/1b clinical trial. Additionally, two patients experienced stable disease (22.2%).
The responses are durable and deepen over time, with two patients remaining on treatment for over one year.
The company noted that the data support its decision to advance NX-5948 into the ongoing Phase 1b expansion cohort in patients who have previously received at least one prior line of therapy including a BTK inhibitor and patients presenting with Bing-Neel syndrome, a rare form of WM with central nervous system involvement where NX-5948's ability to penetrate the brain may offer a distinct advantage.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.